These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 6268598)

  • 1. Synergistic activity of cefoperazone in combination with beta-lactamase inhibitors.
    Fu KP; Neu HC
    J Antimicrob Chemother; 1981 Mar; 7(3):287-92. PubMed ID: 6268598
    [No Abstract]   [Full Text] [Related]  

  • 2. Synergistic activity of piperacillin in combination with beta-lactamase inhibitors.
    Neu HC; Fu KP
    Antimicrob Agents Chemother; 1980 Oct; 18(4):582-5. PubMed ID: 6255862
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activity of cefoperazone and two beta-lactamase inhibitors, sulbactam and clavulanic acid, against Bacteroides spp. correlated with beta-lactamase production.
    Crosby MA; Gump DW
    Antimicrob Agents Chemother; 1982 Sep; 22(3):398-405. PubMed ID: 6291451
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bactericidal activity of cefoperazone with CP-45,899 against large inocula of beta-lactamase-producing Haemophilus influenzae.
    Yu PK; Washington JA
    Antimicrob Agents Chemother; 1981 Jul; 20(1):63-5. PubMed ID: 6269484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In-vitro evaluation of the four beta-lactamase inhibitors: BRL42715, clavulanic acid, sulbactam, and tazobactam.
    Muratani T; Yokota E; Nakane T; Inoue E; Mitsuhashi S
    J Antimicrob Chemother; 1993 Sep; 32(3):421-9. PubMed ID: 8262864
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of beta-lactamase inhibitors on the antimicrobial activity of cefoperazone, cefotaxime, and ceftizoxime against aerobic and anaerobic beta-lactamase producing bacteria.
    Fuchs PC; Jones RN; Barry AL
    Diagn Microbiol Infect Dis; 1987 Sep; 8(1):61-5. PubMed ID: 3501975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity of 13 beta-lactam agents combined with BRL 42715 against beta-lactamase producing gram-negative bacteria compared to combinations with clavulanic acid, tazobactam and sulbactam.
    Piddock LJ; Jin YF; Turner HL
    J Antimicrob Chemother; 1993 Jan; 31(1):89-103. PubMed ID: 8383105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evolution of beta-lactamase inhibitors.
    Rolinson GN
    Rev Infect Dis; 1991; 13 Suppl 9():S727-32. PubMed ID: 1656513
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro evaluation of SF-2103A, a novel carbapenem antibiotic, as a beta-lactamase inhibitor.
    Niwa T; Yoshida T; Tamura A; Kazuno Y; Inouye S; Ito T; Kojima M
    J Antibiot (Tokyo); 1986 Jul; 39(7):943-55. PubMed ID: 3019978
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 'Beta-lactams' as beta-lactamase inhibitors.
    Cole M
    Philos Trans R Soc Lond B Biol Sci; 1980 May; 289(1036):207-23. PubMed ID: 6109317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tazobactam-piperacillin compared with sulbactam-ampicillin, clavulanic acid-ticarcillin, sulbactam-cefoperazone, and piperacillin for activity against beta-lactamase-producing bacteria isolated from patients with complicated urinary tract infections.
    Nomura S; Hanaki H; Nagayama A
    J Chemother; 1997 Apr; 9(2):89-94. PubMed ID: 9176745
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of inhibitors of beta-lactamases on beta-lactamase extracts and on intact cells.
    Li JT; Moosdeen F; Williams JD
    J Antimicrob Chemother; 1982 Apr; 9(4):287-96. PubMed ID: 6282800
    [No Abstract]   [Full Text] [Related]  

  • 13. Correlation of the effect of beta-lactamase inhibitors on the beta-lactamase in growing cultures of gram-negative bacteria with their effect on the isolated beta-lactamase.
    Easton CJ; Knowles JR
    Antimicrob Agents Chemother; 1984 Sep; 26(3):358-63. PubMed ID: 6095753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Variation in the potentiation of beta-lactam antibiotic activity by clavulanic acid and sulbactam against multiply antibiotic-resistant bacteria.
    Aldridge KE; Sanders CV; Marier RL
    J Antimicrob Chemother; 1986 Apr; 17(4):463-9. PubMed ID: 3011724
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activity of cefodizime (HR-221) in combination with beta-lactamase inhibitors.
    Segatore B; Perilli M; Franceschini N; Setacci D; Oratore A; Amicosante G
    J Chemother; 1993 Jun; 5(3):147-50. PubMed ID: 8396624
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic activity of mecillinam in combination with the beta-lactamase inhibitors clavulanic acid and sulbactam.
    Neu HC
    Antimicrob Agents Chemother; 1982 Sep; 22(3):518-9. PubMed ID: 6291454
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beta-lactamase inactivation by mechanism-based reagents.
    Fisher J; Belasco JG; Charnas RL; Khosla S; Knowles JR
    Philos Trans R Soc Lond B Biol Sci; 1980 May; 289(1036):309-19. PubMed ID: 6109326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative in vitro activity of beta-lactam/beta-lactamase inhibitor combinations against gram negative bacteria.
    Mohanty S; Singhal R; Sood S; Dhawan B; Das BK; Kapil A
    Indian J Med Res; 2005 Nov; 122(5):425-8. PubMed ID: 16456257
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activities of piperacillin or cefoperazone alone and in combination with beta-lactamase inhibitors against gram-negative bacilli.
    Kuo HY; Wang FD; Yen YF; Lin ML; Liu CY
    New Microbiol; 2009 Jan; 32(1):49-55. PubMed ID: 19382669
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sulbactam/cefoperazone versus cefotaxime for the treatment of moderate-to-severe bacterial infections: results of a randomized, controlled clinical trial.
    Li JT; Lu Y; Hou J; Chen YF; Miao JZ; Jia YX; Hou J; Zhang XZ; Chen DK; Hu WZ; Li LJ; Liu DM; Wang Z; Wu J; Gu JM; Wang HL; Zhang YL; Sun L
    Clin Infect Dis; 1997 Mar; 24(3):498-505. PubMed ID: 9114206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.